Xiamen Kingdomway Group Company
金达威
002626
Shenzhen Stock Exchange
Company Profile
As a leading domestic innovator in synthetic biology, the company possesses strong research and innovation capabilities, dedicated to leveraging emerging synthetic biology technologies to develop and produce high-quality products aligned with China’s national sustainability strategy. With years of deep industry cultivation, the company has built a comprehensive synthetic biology platform, robust biosynthesis R&D capabilities, and a large-scale enzyme library. By continuously increasing investment in the field of synthetic biology, the company has been recognized as a National Enterprise Technology Center and was named a “2022 National Intellectual Property Demonstration Enterprise” by the China National Intellectual Property Administration. To date, the company has undertaken nine national-level science and technology projects, including the “863 Program,” the National Torch Program, and the National Marine Demonstration Project, as well as 34 science and technology research projects at the provincial, municipal, and district levels. The company’s core technologies and products have received numerous national and provincial-level awards, such as the First Prize of Science and Technology Progress from the China National Light Industry Council, the First Prize of the Fujian Provincial Patent Award, the Second Prize of the Xiamen Municipal Patent Award, and the Third Prize of Xiamen Science and Technology Progress Award. The company’s subsidiary, Inner Mongolia Kingdomway Pharmaceutical Limited, has been honored as a “National Green Factory” by the Ministry of Industry and Information Technology and recognized as a “2023 National Intellectual Property Demonstration Enterprise” by the National Intellectual Property Administration. Guided by its “Ingredients + Brands” dual-engine strategy, the company maintains a leading position in technological innovation, product development, and brand strategy within the industry. With advantages in high purity, high concentration, and high quality, the company’s coenzyme Q10 has been recognized by the Ministry of Industry and Information Technology as a national single champion product. It is now the world’s largest producer of coenzyme Q10 and a major producer of vitamin A, vitamin D3, microalgal DHA, plant-based ARA, vitamin K2, NMN, and other raw materials. Inner Mongolia Kingdomway Pharmaceutical Limited has completed the construction of a 1.5x capacity expansion project for its coenzyme Q10 production line, which is expected to enter trial production soon. After expansion, the production capacity of coenzyme Q10 will reach 920 tons per year, further strengthening the company’s market leadership in this field. At the same time, leveraging core technologies such as green manufacturing through synthetic biology, microbial fermentation, chemical synthesis, natural product extraction, and microencapsulation technology, along with its high-purity, high-quality ingredients, the company enjoys competitive advantages in both the B2B raw materials sector and the B2C health supplement sector. In mature overseas markets, the company owns a portfolio of internationally recognized brands including Doctor's Best, Viactiv, Zipfizz, and RxSugar. Several of the company’s branded products rank among the top in sales within their categories on global e-commerce platforms such as Amazon and iHerb, as well as membership clubs and large retail chains such as Costco, Sam's Club, and Walmart.
Full description
The company is driven by synthetic biology as its core technology and is engaged in the research, production, and sales of nutritional and health foods (including raw materials and finished products), as well as feed additives, through advanced biomanufacturing and chemical synthesis processes. According to the "National Economic Industry Classification" (GB/T 4754-2017) issued by the National Bureau of Statistics of China, the company’s health food ingredients and feed additive businesses fall under the category of “Manufacturing of Food and Feed Additives” (C1495), while its finished health food products are classified under “Manufacturing of Health Foods” (C1492). The production of health food ingredients and feed additives is primarily carried out domestically and features high export ratios, as these are globally competitive products. In contrast, the production, sales, and brand operations of finished health food products are mainly conducted overseas. The company applies synthetic biology as a foundational technology across the large-scale production of most raw material products and actively explores new product development using synthetic biology. Its raw material portfolio includes coenzyme Q10, DHA, ARA, vitamin A, vitamin D3, vitamin K2, nattokinase, PQQ, NMN, astaxanthin, and inositol series products. Its feed additive products include vitamin A and vitamin D3. Additionally, the company manufactures pharmaceutical ingredients such as praziquantel, alanyl-glutamine, and oxiracetam, which are used for the treatment and prevention of schistosomiasis and cysticercosis, parenteral nutrition, brain injuries and related neurological dysfunction, as well as memory and cognitive disorders. In the field of finished health food products, the company owns several brands, including Doctor's Best, Zipfizz, Viactiv, RxSugar in the United States, and Jinlexin in China. Its U.S. subsidiary, VitaBest, provides contract manufacturing services for nutritional supplements in the form of capsules, tablets, and powders. A new softgel production line at the VitaBest facility is currently under construction and is expected to commence operations in the second half of 2025.With operations spanning raw material supply, formulation production, brand management, and distribution channels, the company has established itself as a full-industry-chain enterprise in the health food sector.